Cargando…

Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept

Major advances in drug development have led to the introduction of biologic disease- modifying drugs for the treatment of rheumatoid arthritis, which has resulted in unprecedented improvement in outcomes for many patients. These agents have been found to be effective in reducing clinical signs and s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malaviya, Anshuman P, Östör, Andrew JK
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429155/ https://www.ncbi.nlm.nih.gov/pubmed/22936845 http://dx.doi.org/10.2147/PPA.S23786

Ejemplares similares

Common Transcriptomic Effects of Abatacept and Other DMARDs on Rheumatoid Arthritis Synovial Tissue
por: Triaille, Clement, et al.
Publicado: (2021)

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab
por: Negoescu, Andra F., et al.
Publicado: (2014)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA
por: Harrold, Leslie R., et al.
Publicado: (2021)

Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
por: Genovese, M C, et al.
Publicado: (2011)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study
por: Muraoka, Sei, et al.
Publicado: (2021)

Subcutaneous abatacept in rheumatoid arthritis: A real-life experience
por: Sarmiento-Monroy, Juan Camilo, et al.
Publicado: (2019)

Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database
por: Harnett, James, et al.
Publicado: (2016)

Diabetes-Related Complications and Costs in Medicare Beneficiaries with Comorbid Rheumatoid Arthritis and Diabetes Treated with Abatacept Versus Other Targeted DMARDs
por: Patel, Vardhaman, et al.
Publicado: (2022)

Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry
por: Choquette, Denis, et al.
Publicado: (2019)

Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: Addressing treatment outside the current NICE guidance
por: Chiu, Yee, et al.
Publicado: (2012)

Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis
por: Rakieh, Chadi, et al.
Publicado: (2014)

Usability and Acceptability of the Abatacept Pre-Filled Autoinjector for the Subcutaneous Treatment of Rheumatoid Arthritis
por: Schiff, Michael, et al.
Publicado: (2016)

Effectiveness of electronic drug monitoring feedback to increase adherence in patients with RA initiating a biological DMARD: a randomised clinical trial
por: Hebing, Renske CF, et al.
Publicado: (2022)

A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations
por: Wells, Alvin F, et al.
Publicado: (2014)

Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis
por: D’Agostino, Maria-Antonietta, et al.
Publicado: (2017)

Population Pharmacokinetics and Exposure‐Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis
por: Li, Xiaohui, et al.
Publicado: (2018)

The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice
por: Roberts, Lynden, et al.
Publicado: (2017)

Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals
por: Menon, Deepak, et al.
Publicado: (2022)

Development and Validation of Adherence Score for Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs
por: Abdul Razak, Salmi, et al.
Publicado: (2020)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
por: Coates, Laura C, et al.
Publicado: (2017)

Model‐Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis
por: Gandhi, Yash, et al.
Publicado: (2021)

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020)

Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients
por: Nived, Per, et al.
Publicado: (2020)

Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
por: Pang, Mengduan, et al.
Publicado: (2022)

Recovery in Special Emphasis Populations
por: Wagner, Eric F., et al.
Publicado: (2020)

Biological or targeted synthetic DMARDs increase COVID-19 severity
Publicado: (2021)

Particle Nanoarchitectonics for Nanomedicine and Nanotherapeutic Drugs with Special Emphasis on Nasal Drugs and Aging
por: Aziz, Tariq, et al.
Publicado: (2023)

Correction to: Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients
por: Nived, Per, et al.
Publicado: (2020)

Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis
por: Akter, Ripa, et al.
Publicado: (2020)

Therapeutic drug repositioning with special emphasis on neurodegenerative diseases: Threats and issues
por: Kakoti, Bibhuti Bhusan, et al.
Publicado: (2022)

Polymeric Micellar Systems—A Special Emphasis on “Smart” Drug Delivery
por: Negut, Irina, et al.
Publicado: (2023)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis
por: Peterson, Jeffrey D, et al.
Publicado: (2010)

Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?
por: Lwin, May, et al.
Publicado: (2020)

Pycnodysostosis with Special Emphasis on Dentofacial Characteristics
por: Khoja, Aisha, et al.
Publicado: (2015)

Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
por: Truchetet, Marie-Elise, et al.
Publicado: (2016)

Molecular mechanisms of resistance to disease modifying antirheumatic drugs (DMARDs)
por: Jansen, G, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_cg8428blv7ro2bath6nj6sf915